enzastaurin has been researched along with Disease Models, Animal in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Andruska, A; Austin, ED; Boehm, M; Dannewitz Prosseda, S; Donato, M; Huebner, K; Khatri, P; Kuramoto, K; Loyd, JE; Metzger, RJ; Miyagawa, K; Saldivar, JC; Solow-Cordero, D; Spiekerkoetter, E; Sudheendra, D; Tian, X; Wang, L; Wheeler, L; Zhang, F | 1 |
| Chang, H; Chen, GA; Chen, J; Chen, Y; Evans, K; Qiu, L; Reece, D; Saha, MN; Yang, Y | 1 |
| Bachir, S; Bedja, D; Caulfield, MJ; Dietz, HC; Doyle, AJ; Doyle, JJ; Ehsan, H; Habashi, JP; Huso, D; Huso, N; Judge, DP; Lindsay, ME; Myers, L; Rusholme, B; Schoenhoff, F; Squires, O; Thomas, CJ; Van Eyk, JE; Whitworth, RE; Wilson, NK | 1 |
| Bang, YJ; Byun, HJ; Kim, W; Lee, HS; Lee, SH; Lee, SM; Myung, SJ; Yang, JI; Yoon, JH | 1 |
| Hayes, DN; Shores, CG; Yin, X | 1 |
| Chen, L; Goldman, B; Jenks, S; Leitgets, M; Lund, F; Mehta, K; Mehta, M; Misra, R; Mohan, C; Oleksyn, D; Pulvino, M; Sanz, I; Schwartz, G; Tipton, C; Vosoughi, A; Zhao, J | 1 |
| Dudek, AZ; Ericson, ME; Farassati, F; Gallus, NJ; Jasinski, P; Terai, K; Zwolak, P | 1 |
8 other study(ies) available for enzastaurin and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.
Topics: Acid Anhydride Hydrolases; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Female; Genes, Modifier; Humans; Indoles; Lung; Male; Mice; Mice, Inbred C57BL; Neoplasm Proteins; Rats; Rats, Sprague-Dawley; Signal Transduction | 2019 |
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Transplantation; Phosphorylation; Primary Cell Culture; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Survival Analysis | 2015 |
A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome.
Topics: Adult; Animals; Antihypertensive Agents; Calcium Channel Blockers; Child; Child, Preschool; Disease Models, Animal; Humans; Hydralazine; Indoles; Longitudinal Studies; MAP Kinase Signaling System; Marfan Syndrome; Mice, Inbred C57BL; Protein Kinase C beta; Receptor, Angiotensin, Type 1; Survival Analysis; Treatment Outcome | 2015 |
Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis.
Topics: Animals; Apoptosis; Body Weight; Carbon Tetrachloride; Cell Line, Transformed; Disease Models, Animal; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Mitochondria; Organ Size; Pravastatin; Protein Kinase C; Protein Kinase Inhibitors; Thioacetamide | 2010 |
Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Random Allocation; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2011 |
Protein kinase Cβ is required for lupus development in Sle mice.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Survival; Disease Models, Animal; Humans; Indoles; Lupus Erythematosus, Systemic; Mice; Mice, Congenic; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors | 2013 |
Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Topics: Animals; Apoptosis; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, SCID; Neovascularization, Pathologic; Osteoclasts; Pain; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; ras Proteins; Signal Transduction; Tumor Burden | 2008 |